Insights & Resources

J.P. Morgan's Q1 2025 biopharma and medtech reports reveal larger deals, global growth and financial strategies shaping the life sciences industry.

Discover how outsourcing in pharmaceutical manufacturing enhances quality, ensures compliance and mitigates risks in a rapidly evolving industry.

Download our white paper to learn how to even begin to measure and report GHG emissions.

J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.

Weaver’s overview of the SEC’s 2025 examination priorities describe practices by investment advisers and others that may come under SEC review.

The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.

PCI DSS sets the standard for payment card security in higher education detailing compliance levels, reporting requirements and strategies to protect data.

As Local Law 97 mandates emission reductions for large buildings in NYC, property owners are taking proactive steps to ensure compliance and avoid fines.

The DOE has introduced a national definition of a zero emissions building, setting clear criteria for energy-efficient buildings to reduce greenhouse gas emissions.

As the food and beverage industry has served up big changes in recent years, Weaver’s strategies may help food, beverage and hospitality businesses navigate the leading trends of 2024.

Discover how the Inflation Reduction Act of 2022 boosts tax deductions for energy efficient commercial buildings with major incentives reaching up to $5 per sq. ft.

If FinCEN’s proposed rule is adopted, SEC Registered Investment Advisers and Exempt Reporting Advisers would be subject to FinCEN’s AML and CFT requirements.